UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

465 SGI-110, a Novel Second Generation DNa Hypomethylating Agent, Enhances Sorafenib Activity and Alters Methylation Signature of HCC Cell Lines

European journal of cancer (1990), 2012-11, Vol.48, p.144-144

2012

Volltextzugriff (PDF)

S192: SINGLE‐CELL RNA PROFILING OF MYELOFIBROSIS PATIENTS REVEALS PELABRESIB‐INDUCED DECREASE OF MEGAKARYOCYTIC PROGENITORS AND NORMALIZATION OF CD4+ T CELLS IN PERIPHERAL BLOOD

HemaSphere, 2022-06, Vol.6, p.93-94

2022

Volltextzugriff (PDF)

COMBINATION OF IRAK4 (CA‐4948) AND BTK (VECABRUTINIB) INHIBITORS SHOW SUPERIOR EFFICACY IN PRECLINICAL MODELS OF ABC DLBCL TUMORS CONTAINING MYD88‐L265P MUTATIONS

Hematological oncology, 2019-06, Vol.37 (S2), p.512-512

2019

Volltextzugriff (PDF)

134 Epigenetic immunomodulation by SGI-110 combined with immune checkpoint blockade for new therapeutic strategies

European journal of cancer (1990), 2014-11, Vol.50, p.47-47

2014

Volltextzugriff (PDF)

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma

British journal of cancer, 2011-11, Vol.105 (10), p.1563-1573

2011

Volltextzugriff (PDF)

Generation of an endogenous DNA-methylating agent by nitrosation in Escherichia coli

Journal of Bacteriology, 1996-09, Vol.178 (17), p.5105-5111

1996

Volltextzugriff (PDF)

PDK1 inhibitor SNS-510 shows synergy with targeted cancer therapies in solid tumor and hematologic cancer models

European journal of cancer (1990), 2020-10, Vol.138, p.S45-S45

2020

Volltextzugriff (PDF)

193 Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines

European journal of cancer supplements, 2010, Vol.8 (7), p.65-65

2010

Volltextzugriff (PDF)

171 Amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with etoposide (VP-16) in small cell lung cancer (SCLC) cell lines and xenografts

European journal of cancer supplements, 2010, Vol.8 (7), p.59-59

2010

Volltextzugriff (PDF)

SGI-110: DNA Methyltransferase Inhibitor Oncolytic

Drugs of the future, 2013-08, Vol.38 (8), p.535-543

2013

Volltextzugriff (PDF)

Determination of cadmium ions in water by a novel electrochemiluminescence method

Analytica chimica acta, 1998-11, Vol.373 (2), p.111-117

1998

Volltextzugriff (PDF)

547 Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidinecontaining demethylating dinucleotide

European journal of cancer supplements, 2010, Vol.8 (7), p.173-174

2010

Volltextzugriff (PDF)

A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study

Annals of oncology, 2015-11, Vol.26, p.viii5-viii5

2015

Volltextzugriff (PDF)

478 POSTER Human cancer cells are sensitized to voreloxin (formerly SNS-595) after modulation of DNA double strand break repair

European journal of cancer supplements, 2008, Vol.6 (12), p.153-153

2008

Volltextzugriff (PDF)

283 POSTER Phase 1 trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients

European journal of cancer supplements, 2008, Vol.6 (12), p.91-92

2008

Volltextzugriff (PDF)

Pharmacologic Disruption of Base Excision Repair Sensitizes Mismatch Repair-deficient and -proficient Colon Cancer Cells to Methylating Agents

Clinical cancer research, 1999-10, Vol.5 (10), p.2908-2917

1999

Volltextzugriff (PDF)

Optical properties of short pitch cholesteric liquid crystals

Liquid crystals, 2001-04, Vol.28 (4), p.591-598

2001

Volltextzugriff (PDF)

Immunomodulatory Activity of SGI-110, a Second Generation Hypomethylating Agent

Annals of oncology, 2013-03, Vol.24, p.i7-i7

2013

Volltextzugriff (PDF)

502 POSTER SNS-314, a selective Aurora kinase inhibitor with potent, pre-clinical antitumour activity, shows broad therapeutic potential in combination with standard chemotherapeutics and synergy with microtubule targeted agents

European journal of cancer supplements, 2007, Vol.5 (4), p.90-90

2007

Volltextzugriff (PDF)

PS1148 PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE‐ESCALATION AND COHORT‐EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B‐CELL MALIGNANCIES

HemaSphere, 2019-06, Vol.3 (S1), p.520-n/a

2019

Volltextzugriff (PDF)

Liquid crystal comb polymer with polar mesogenic and aliphatic side groups II. Noise of the scattered light

Liquid crystals, 2002-03, Vol.29 (3), p.405-411

2002

Volltextzugriff (PDF)

Liquid crystal comb polymer with polar mesogenic and aliphatic side groups I. Preparation and structural properties

Liquid crystals, 2002-03, Vol.29 (3), p.397-404

2002

Volltextzugriff (PDF)

SGI-110. DNA methyltransferase inhibitor, Oncolytic

Drugs of the future, 2013, Vol.38 (8), p.535

2013

Volltextzugriff (PDF)

Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization

Cancer research (Chicago, Ill.), 2003-02, Vol.63 (4), p.838-846

2003

Volltextzugriff (PDF)

1 – 25 von 383

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(284)
Mit Volltextzugriff
(296)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

465 SGI-110, a Novel Second Generation DNa Hypomethylating Agent, Enhances Sorafenib Activity and Alters Methylation Signature of HCC Cell Lines

S192: SINGLE‐CELL RNA PROFILING OF MYELOFIBROSIS PATIENTS REVEALS PELABRESIB‐INDUCED DECREASE OF MEGAKARYOCYTIC PROGENITORS AND NORMALIZATION OF CD4+ T CELLS IN PERIPHERAL BLOOD

COMBINATION OF IRAK4 (CA‐4948) AND BTK (VECABRUTINIB) INHIBITORS SHOW SUPERIOR EFFICACY IN PRECLINICAL MODELS OF ABC DLBCL TUMORS CONTAINING MYD88‐L265P MUTATIONS

134 Epigenetic immunomodulation by SGI-110 combined with immune checkpoint blockade for new therapeutic strategies

S198: BET INHIBITOR PELABRESIB (CPI‐0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR‐NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma

Generation of an endogenous DNA-methylating agent by nitrosation in Escherichia coli

PDK1 inhibitor SNS-510 shows synergy with targeted cancer therapies in solid tumor and hematologic cancer models

193 Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines

171 Amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with etoposide (VP-16) in small cell lung cancer (SCLC) cell lines and xenografts

SGI-110: DNA Methyltransferase Inhibitor Oncolytic

Determination of cadmium ions in water by a novel electrochemiluminescence method

547 Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidinecontaining demethylating dinucleotide

A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study

478 POSTER Human cancer cells are sensitized to voreloxin (formerly SNS-595) after modulation of DNA double strand break repair

283 POSTER Phase 1 trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients

Pharmacologic Disruption of Base Excision Repair Sensitizes Mismatch Repair-deficient and -proficient Colon Cancer Cells to Methylating Agents

Optical properties of short pitch cholesteric liquid crystals

Immunomodulatory Activity of SGI-110, a Second Generation Hypomethylating Agent

502 POSTER SNS-314, a selective Aurora kinase inhibitor with potent, pre-clinical antitumour activity, shows broad therapeutic potential in combination with standard chemotherapeutics and synergy with microtubule targeted agents

PS1148 PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE‐ESCALATION AND COHORT‐EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B‐CELL MALIGNANCIES

Liquid crystal comb polymer with polar mesogenic and aliphatic side groups II. Noise of the scattered light

Liquid crystal comb polymer with polar mesogenic and aliphatic side groups I. Preparation and structural properties

SGI-110. DNA methyltransferase inhibitor, Oncolytic

Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization

Suchergebnisse filtern